CRNX — Crinetics Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $3.03bn
- $1.68bn
- $1.04m
- 48
- 11
- 45
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.29 | ||
| Price to Tang. Book | 2.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2,918.81 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.65% | ||
| Return on Equity | -32.02% | ||
| Operating Margin | -32613.47% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.07 | 1.08 | 4.74 | 4.01 | 1.04 | 4.65 | 37.21 | -2.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Directors
- Wendell Wierenga NEC (73)
- R. Scott Struthers PRE (59)
- Marc Wilson CFO (42)
- Jeff Knight COO (51)
- Garlan Adams GCN
- Alan Krasner OTH (57)
- Ajay Madan OTH (53)
- Camille Bedrosian IND (68)
- Rogerio Coelho IND
- Matthew Fust IND (56)
- Weston Nichols IND (36)
- Stephanie Okey IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 18th, 2008
- Public Since
- July 18th, 2018
- No. of Shareholders
- 10
- No. of Employees
- 437
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 93,629,118
- Address
- 10222 Barnes Canyon Road, Bldg. #2, SAN DIEGO, 92121
- Web
- https://www.crinetics.com/
- Phone
- +1 8584506464
- Auditors
- BDO USA, LLP
Upcoming Events for CRNX
Q1 2025 Crinetics Pharmaceuticals Inc Earnings Call
Crinetics Pharmaceuticals Inc Annual Shareholders Meeting
Crinetics Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Release
Similar to CRNX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Crinetics Pharmaceuticals share price?
As of Today at 20:06 UTC, shares in Crinetics Pharmaceuticals are trading at $32.39. This share price information is delayed by 15 minutes.
How has the Crinetics Pharmaceuticals share price performed this year?
Shares in Crinetics Pharmaceuticals last closed at $32.39 and the price had moved by -23.41% over the past 365 days. In terms of relative price strength the Crinetics Pharmaceuticals share price has underperformed the S&P500 Index by -29.3% over the past year.
What are the analyst and broker recommendations for Crinetics Pharmaceuticals?
The overall consensus recommendation for Crinetics Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Crinetics Pharmaceuticals dividend yield?
Crinetics Pharmaceuticals does not currently pay a dividend.
Does Crinetics Pharmaceuticals pay a dividend?
Crinetics Pharmaceuticals does not currently pay a dividend.
When does Crinetics Pharmaceuticals next pay dividends?
Crinetics Pharmaceuticals does not currently pay a dividend.
How do I buy Crinetics Pharmaceuticals shares?
To buy shares in Crinetics Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Crinetics Pharmaceuticals?
As of the previous close price of $32.39, shares in Crinetics Pharmaceuticals had a market capitalisation of $3.03bn.
Where are Crinetics Pharmaceuticals shares listed?
Here are the trading details for Crinetics Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CRNX
What kind of share is Crinetics Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Crinetics Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Crinetics Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Crinetics Pharmaceuticals is $75.86. That is 134.21% above the last closing price of $32.39.
Analysts covering Crinetics Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$4.10 for the next financial year.
Find out moreWhat is the trend in the Crinetics Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Crinetics Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -41.1%.
As of the last closing price of $32.39, shares in Crinetics Pharmaceuticals were trading -30.95% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Crinetics Pharmaceuticals PE Ratio?
The Crinetics Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $32.39.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals' management team is headed by:
- Wendell Wierenga - NEC
- R. Scott Struthers - PRE
- Marc Wilson - CFO
- Jeff Knight - COO
- Garlan Adams - GCN
- Alan Krasner - OTH
- Ajay Madan - OTH
- Camille Bedrosian - IND
- Rogerio Coelho - IND
- Matthew Fust - IND
- Weston Nichols - IND
- Stephanie Okey - IND